Selecting the Right Targets for Fragment‐Based Drug Discovery

[1]  Binh Vu,et al.  Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. , 2013, ACS medicinal chemistry letters.

[2]  BinQing Wei,et al.  Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase. , 2013, Bioorganic & medicinal chemistry letters.

[3]  V. Marx.  Structural biology: 'seeing' crystals the XFEL way , 2014, Nature Methods.

[4]  Philipp Baaske,et al.  MicroScale Thermophoresis: Interaction analysis and beyond , 2014 .

[5]  B. Finzel,et al.  Fragment-based identification of an inducible binding site on cell surface receptor CD44 for the design of protein-carbohydrate interaction inhibitors. , 2014, Journal of medicinal chemistry.

[6]  Rutger H A Folmer,et al.  Fragment screening to predict druggability (ligandability) and lead discovery success. , 2011, Drug discovery today.

[7]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[8]  L. Cantley,et al.  Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. , 2012, Chemistry & biology.

[9]  Nagasuma Chandra,et al.  PocketDepth: a new depth based algorithm for identification of ligand binding sites in proteins. , 2008, Journal of structural biology.

[10]  G. Bodenhausen,et al.  Exploring Weak Ligand–Protein Interactions by Long-Lived NMR States: Improved Contrast in Fragment-Based Drug Screening , 2014, Angewandte Chemie.

[11]  L. Levin,et al.  Kinetic Properties of “Soluble” Adenylyl Cyclase , 2003, The Journal of Biological Chemistry.

[12]  Paul N. Mortenson,et al.  Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors. , 2012, ACS medicinal chemistry letters.

[13]  A. Wittinghofer,et al.  Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site. , 2014, Journal of medicinal chemistry.

[14]  A. Good,et al.  The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[15]  Meir Glick,et al.  Inside the Mind of a Medicinal Chemist: The Role of Human Bias in Compound Prioritization during Drug Discovery , 2012, PloS one.

[16]  J. Wells,et al.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.

[17]  S. Barelier,et al.  Fragment-based deconstruction of Bcl-xL inhibitors. , 2010, Journal of medicinal chemistry.

[18]  Identification of High‐Affinity β‐Secretase Inhibitors Using Fragment‐Based Lead Generation , 2008 .

[19]  Tom Halgren,et al.  New Method for Fast and Accurate Binding‐site Identification and Analysis , 2007, Chemical biology & drug design.

[20]  Susan M. Boyd,et al.  Fragment library design: efficiently hunting drugs in chemical space. , 2010, Drug discovery today. Technologies.

[21]  Harren Jhoti,et al.  The 'rule of three' for fragment-based drug discovery: where are we now? , 2013, Nature Reviews Drug Discovery.

[22]  P. Johnston,et al.  SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma , 2013, Cell Death and Disease.

[23]  D. Altshuler,et al.  Validating therapeutic targets through human genetics , 2013, Nature Reviews Drug Discovery.

[24]  R. Nussinov,et al.  Allostery and population shift in drug discovery. , 2010, Current opinion in pharmacology.

[25]  Ivet Bahar,et al.  ProDy: Protein Dynamics Inferred from Theory and Experiments , 2011, Bioinform..

[26]  Stéphanie Pérot,et al.  Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. , 2010, Drug discovery today.

[27]  Richard M. Jackson,et al.  Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites , 2005, Bioinform..

[28]  G. Chessari,et al.  Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. , 2015, Journal of medicinal chemistry.

[29]  M. Congreve,et al.  Crystal Structure of Human Soluble Adenylate Cyclase Reveals a Distinct, Highly Flexible Allosteric Bicarbonate Binding Pocket , 2014, ChemMedChem.

[30]  J. Rabinowitz,et al.  Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation , 2012, Proceedings of the National Academy of Sciences.

[31]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[32]  Brandon J. Bravo,et al.  Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). , 2014, Bioorganic & medicinal chemistry letters.

[33]  R. Hillig,et al.  A structural biology view of target drugability , 2008, Expert opinion on drug discovery.

[34]  S. P. Andrews,et al.  Structure‐Based and Fragment‐Based GPCR Drug Discovery , 2014, ChemMedChem.

[35]  J. Mestan,et al.  Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. , 2010, Journal of the American Chemical Society.

[36]  Marcel L Verdonk,et al.  Identification of inhibitors of protein kinase B using fragment-based lead discovery. , 2007, Journal of medicinal chemistry.

[37]  Christopher W Murray,et al.  Efficient exploration of chemical space by fragment-based screening. , 2014, Progress in biophysics and molecular biology.

[38]  Jon Winter,et al.  Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. , 2012, Journal of medicinal chemistry.

[39]  D. Goodsell,et al.  Automated prediction of ligand‐binding sites in proteins , 2007, Proteins.

[40]  Dima Kozakov,et al.  Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..

[41]  A. Hopkins,et al.  The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.

[42]  Eyal Gottlieb,et al.  Serine is a natural ligand and allosteric activator of pyruvate kinase M2 , 2012, Nature.

[43]  Daniel R. Caffrey,et al.  Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.

[44]  Andrew J. Woodhead,et al.  Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function , 2012, Nature chemical biology.

[45]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[46]  P. Hajduk,et al.  Predicting protein druggability. , 2005, Drug discovery today.

[47]  A. Stamford,et al.  Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. , 2013, Current opinion in chemical biology.

[48]  Liang Lin,et al.  Contextualized trajectory parsing with spatiotemporal graph. , 2013, IEEE transactions on pattern analysis and machine intelligence.

[49]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[50]  W. Jahnke,et al.  Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. , 2010, Nature chemical biology.

[51]  Jean-Louis Reymond,et al.  Virtual Exploration of the Chemical Universe up to 11 Atoms of C, N, O, F: Assembly of 26.4 Million Structures (110.9 Million Stereoisomers) and Analysis for New Ring Systems, Stereochemistry, Physicochemical Properties, Compound Classes, and Drug Discovery , 2007, J. Chem. Inf. Model..

[52]  M Hendlich,et al.  LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. , 1997, Journal of molecular graphics & modelling.

[53]  Christopher W Murray,et al.  Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.

[54]  M. Mansour,et al.  Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design. , 2012, Journal of medicinal chemistry.

[55]  Paul D. Leeson,et al.  The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.

[56]  R. Abagyan,et al.  Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes* , 2005, Molecular & Cellular Proteomics.